Shuttle Pharma's Selective HDAC Inhibitor Exhibits Ataxia-Telangiectasia Mutated Protein Activation And Modulation Of ER Expression Resulting In Growth Inhibition Of Estrogen Receptor Positive Breast Cancer Cells, As Reported In 'Public Library Of Science ONE'

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH), ("Shuttle Pharma"), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced the publication of a manuscript reporting on the ability of one of the Company's HDAC inhibitor pre-clinical assets, SP-1-303, which exhibits ataxia-telangiectasia mutated protein (ATM) activation and modulation of estrogen receptor expression resulting in substantial growth inhibition of estrogen receptor positive breast cancer cells (ER + BC).

 

The published manuscript, titled "Dual-targeting class I HDAC inhibitor and ATM activator, SP-1-303, preferentially inhibits estrogen receptor positive breast cancer cell growth," reports the work of Dr. Mira Jung, Professor of Radiation Medicine at Georgetown University Medical Center, and Dr. Scott Grindrod, Shuttle Pharma's Principal Scientist, and was published in PLOS ONE, a peer-reviewed open access journal published by the Public Library of Science (PLOS).